Background: Infections of the bile ducts of betta fish are frequently complicated. Tetracycline antibiotics are commonly used in the treatment of this disease. However, they are not widely used in fish diseases because their resistance has been observed in some of the species. This study describes the prevalence of antibiotic resistance in the bile ducts of betta fish by examining the susceptibility of bacteria isolated from this population. Methods: This study was conducted on a population of betta fish (the genusAchillea lacustris) from the South China Sea, China. The betta fish were purchased from the market, collected by a local veterinarian, and the antibiotic resistance of the bacteria was determined using a bacterial disk method using agar dilution. The bacterial strains were then incubated at 35 °C for 24 h in a standard culture bottle at a total of 1.4 g/ml. The antibiotic susceptibility of the bacterial strains was determined using a bacterial disk method. Results: The antibiotics susceptibility of the bacterial strains was determined by the disk method using the agar dilution. The antibiotic resistance of the bacterial strains was determined by the method of microbroth dilution. The bacterial strains were found to be resistant to all antibiotics tested. Conclusion: The prevalence of antibiotic resistance in betta fish in China has been reported to be as high as in other countries. The antibiotics susceptibility of the bacterial strains were found to be low in this population. However, in the present study, the prevalence of antibiotic resistance in betta fish in China was high, which may be due to the low antibiotic susceptibility in this species. This study is the first study of the occurrence of antibiotic resistance in betta fish.
Citation:Huang, Y., Xia, R., Zhang, B., Xia, Q., and Zhu, Z. (2014) The prevalence of antibiotic resistance in betta fish by the disk method. PLoS ONE 15(6): e7767. https://doi.org/10.1371/journal.pone.017767
Editor:Barry D. K. Jones, Yale University, United States of America
Received:June 4, 2014;Accepted:September 6, 2014;Published:October 13, 2014
Copyright:© 2014 Hu et al. This is an open-access article distributed under the terms of the, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability:All relevant data are within the paper and its Supporting Information files.
Funding:This study was supported by the Science and Technology Project of China (No. ZY201600423). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests:The authors have declared that no competing interests exist.
Bacterial infections are a major cause of morbidity and mortality in fish, including diseases of the bile ducts of fish, caused by bacteria, parasites and other diseases. The main source of infection is fish, especially fish of the genusAchillea. Infection is highly common in this group, which can cause several diseases, including diseases of the bile ducts of fish, caused by bacteria and parasites. Bacteria are responsible for the growth ofA. lacustrisin the fish, and they are the main cause of infection in the fish. Fish are the source of infection, and the development of bacteria and parasites, including, is one of the most frequent causes. Infections in the bile ducts of fish are caused by bacteria and parasites, and it is important to determine the bacterial and parasite prevalence in these diseases to ensure a good diagnosis.
Theare the major pathogens of bettas and their infectivity to bacteria and parasites.have a high prevalence in the bile ducts of fish, and a number of clinical signs and symptoms have been described in the bile ducts of fish. In this study, the prevalence of antibiotic resistance was determined in the betta fish by the disk method using the agar dilution method. The bacterial disk method was used to detect antibiotic resistance of the antibiotic-resistant bacterial strains.
Tetracycline-induced promoter function is a crucial component of the TetR system. As a bacterium that is sensitive to tetracycline, Tetracycline induced promoters are regulated by a range of enzymes, including HSP70, a protein that is required for Tetracycline-dependent transcription.
In this study, we developed a tetracycline-dependent promoter system that includes a TetR-like promoter and a tetracycline-inducible promoter. The system was constructed by the combined expression of tetracycline-inducible and tetracycline-dependent promoters, allowing for the generation of stable gene expression in transfected cells. The system is expressed under the control of the Tetracycline response element (TRE) but is also expressed in the presence of the TetR-activator. As a result, the induction of the Tetracycline promoter is prevented when the TetR-activator is added to the culture medium.
To further demonstrate the utility of the tetracycline-inducible promoter system, we used a tetracycline-inducible promoter system to overexpress the Tetracycline responsive element (TRE), which is a small molecule that binds to the TetR of the TRE promoter, and then drives the expression of the tetracycline-inducible promoter in transfected cells. The tetracycline-inducible promoter system was then constructed by the combination of a tetracycline-inducible and a tetracycline-inducible promoter, allowing for the generation of stable gene expression in transfected cells.
In addition to Tetracycline, another antibiotic, rifampicin, is known to bind to the tetracycline-inducible promoter and to induce the expression of the tetracycline-inducible promoter in transfected cells. To evaluate the ability of these antibiotics to induce the expression of tetracycline-inducible promoters, we used a tetracycline-inducible promoter system that includes the tetracycline-inducible promoter, which is a tetracycline-dependent promoter.
We first tested the ability of the tetracycline-inducible promoter system to induce the expression of the tetracycline-inducible promoter in cells that were transfected with the tetracycline-inducible promoter. We then used a tetracycline-inducible promoter system to produce a transfected cell line that includes the tetracycline-inducible promoter, which is a tetracycline-dependent promoter.
To determine whether the induction of the tetracycline-inducible promoter is effective, we tested the ability of the tetracycline-inducible promoter system to induce the expression of the tetracycline-inducible promoter in cells that were transfected with the tetracycline-inducible promoter. These transfected cells were also transfected with the tetracycline-inducible promoter, as well as with the tetracycline-inducible promoters of the tetracycline-inducible promoter. The transfected cell lines were also transfected with the tetracycline-inducible promoter, as well as with the tetracycline-inducible promoter of the tetracycline-inducible promoter.
To determine the ability of the tetracycline-inducible promoter to induce the expression of the tetracycline-inducible promoter in cells that were transfected with the tetracycline-inducible promoter, we used a tetracycline-inducible promoter system that includes the tetracycline-inducible promoter, which is a tetracycline-dependent promoter.
To generate a tetracycline-inducible promoter system that includes the tetracycline-inducible promoter, we used the tetracycline-inducible promoter of the tetracycline-inducible promoter, which is a tetracycline-dependent promoter.
Doxycycline is an antibiotic that is used to treat a wide range of bacterial infections, including those affecting the stomach and intestine. It is particularly effective against bacteria that can cause infections of the respiratory, skin, urinary tract, and reproductive system. Doxycycline is available in two different forms – one tablet and one capsule.
Doxycycline is an antibiotic that is prescribed to treat a wide range of bacterial infections, including those affecting the stomach and intestine.
Doxycycline is also used to treat acne and rosacea, to prevent the development of antibiotic-resistant bacteria, and to treat rosacea in women.
Doxycycline can be taken by mouth with or without food. However, it is important to take the full course of doxycycline as prescribed by your healthcare provider.
Doxycycline works by blocking the synthesis of proteins that bacteria produce, which can lead to their eventual death. Doxycycline is used to treat various bacterial infections, including:
Doxycycline is a broad-spectrum antibiotic, meaning it works well against a wide range of bacteria that can cause infections in various parts of the body.
Doxycycline works by inhibiting the synthesis of proteins that bacteria produce, which can lead to their eventual death. Doxycycline is a broad-spectrum antibiotic that works by interfering with bacterial protein synthesis, thus effectively killing bacteria that are unable to take drugs that are specifically designed to treat the conditions.
Doxycycline should be taken as directed by a healthcare provider. Typically, doxycycline is taken twice daily, with or without food. However, it is important to follow your doctor’s advice on how to take the dose and how often to take it.
Swallow doxycycline whole with a full glass of water. It may be taken with or without food. However, it is important to take doxycycline with food to ensure its absorption is intact. If you miss a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take a double dose to make up for a missed one.
If you are taking doxycycline as directed by your healthcare provider, do not take the full course unless instructed by your doctor.
If you miss a dose of doxycycline, take it as soon as you remember.
If you are taking doxycycline to treat bacterial infections, it is important to seek medical attention immediately. If you suspect an overdose, seek medical attention at once.
Avoid taking doxycycline with food or milk if you are allergic to doxycycline or other tetracycline antibiotics.
It is also important to avoid taking doxycycline with dairy products and calcium-fortified juices. These can increase the risk of stomach irritation, which can be dangerous if you take them with dairy products.
FDA has warned people against prescribing the drug to patients with heart attacks and strokes, a new advisory to the agency says.
The drug, which is not approved for the treatment of these conditions, is used to treat men with a condition called atrial fibrillation. Patients with this condition can benefit from the drug's use.
The agency's warning comes after the US Food and Drug Administration (FDA) had warned patients to stop using the drug on their own and to see their GP for any side effects, although the drug is not currently approved for this use.
FDA also warned that the drug is a Schedule IV drug, meaning that it would have no effect on blood pressure.
The agency said that patients should only take the medication if it is medically necessary and recommended by the doctor.
FDA has also warned that patients who have suffered strokes and heart attacks, and have been advised to stop using the drug, are at risk of getting side effects.
The agency said that the drug has a risk of serious adverse effects that have been listed on the labels on the packaging and that are rare.
The agency also warned that the drug's side effects may be serious and that patients should discuss any with their GP before taking the drug.
The agency said that patients with serious side effects and those who are prescribed the drug should immediately stop taking the drug and call the doctor or visit their GP to discuss the side effects.
FDA has advised that patients are to follow the advice of the prescribing doctor.
The agency said that a patient should only take the drug if the doctor advises them to stop using it.
PfizerPfizer LtdAAPTetracycline (FDA) warning letter to drug companiesThe agency advised that patients should take the drug at least 2 hours before having any adverse reaction.
The drug is a medicine that contains the active ingredient tetracycline hydrochloride, which belongs to a group of drugs known as tetracyclines, which is used to treat infections of the skin, bone and joint. It is used to treat many of the conditions that cause pain, inflammation, and swelling in people and animals, including the skin.
FDA says that patients who have heart attacks and strokes may also be advised to stop using the drug, and will need to see their GP.
FDA has warned people against prescribing the drug to patients with heart attacks and strokes, a new advisory to the agency saysFDA has warned patients to stop using the drug on their own and to see their GP for any side effects, although the drug is not currently approved for this use.
FDA has warned patients to stop taking the drug on their own and to see their GP for any side effects, although the drug is not currently approved for this use.
The agency added that it has not yet issued any updates to the agency's guidance.
Stade de France Pharmacy